Gynecologic Oncology

Article	Citations
Editorial board	130
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study	91
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)	88
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	81
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	76
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study	70
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage	64
Molecular testing in the upfront setting for high-grade endometrial cancer: How are we doing?	62
Uterine cancer incidence overtakes colorectal cancer, disproportionately impacting minority women in the United States	62
Quantifying opportunities to reduce high-grade serous ovarian cancer via opportunistic salpingectomy	61
Ovarian-Adnexal Reporting and Data System (O-RADS) for adnexal masses: Are we hitting the mark?	60
Investigating the role of the poly (ADP-ribose) polymerase enzyme family in cervical cancer pathogenesis	60
Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study	56
Obesity and ovarian cancer: Leveraging real-world data for incidence and outcomes using a multicenter nationwide electronic database	56
A phase I, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (Claudin 6 x CD3) T-cell engaging bispecific antibody in advanced solid tumors	54
Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years	52
Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-diethylstilbestrol era	50
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-305	49
2025 Annual Meeting on Women's Cancer – SGO Meeting Insights	49
Prognosis of patients who become pregnant after achieving a complete response with fertility-sparing treatment in early endometrial cancer: A Gynecologic Oncology Research Investigators Collaboration	48
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study	48
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)	48
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor	46
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	46
ChatGPT vs Google: Understanding a patient's perspective on their cancer diagnosis, recommended treatment, and survival outcomes	43

Racial disparities in human papillomavirus vaccination rates and correlation with cervical cancer stage at diagnosis: A retrospective analysis	43
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	43
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	42
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	41
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)	40
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	39
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	37
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	37
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	37
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	37
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis	36
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	35
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	35
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	34
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	34
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	33
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	33
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)	33
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	32
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer	32
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	32
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	32
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	31
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	31
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	31
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)	31
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	31
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	31
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	30
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	30
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	30
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	30
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	30
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	30
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,	30
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)	29
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?	28
Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)	28
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	28
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas	28
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations	28
The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study	28
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	27
RE1 transcription factor is decreased in endometrial cancer	27
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	27
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program	27
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	27
Themes, perspectives, and educational quality of content related to Pap smears on TikTok and YouTube	26
Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	26
The outcome of waiting for radiotherapy in locally advanced cervical cancer	26

Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?	26
The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multicenter evaluation	26
Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center	25
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	25
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	25
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	25
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer	25
The Doc versus the Bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology	25
The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study	25
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs	24
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission	24
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers	24
The 15th Biennial Rivkin Center ovarian cancer research symposium	24
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	24
The promise and perils of biomarker testing in gynecologic cancers	24
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	23
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	23
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	23
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study fr	23
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer	23
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	23
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices	23
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	23
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo	23
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies	23
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis	22
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer	22
Profiling the immune landscape in mucinous ovarian carcinoma	22
CRABP2 – A novel biomarker for high-risk endometrial cancer	22
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma	22
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study	22
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer	22
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study	21
Editorial board	21
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial	21
Response to Alexandre Andre B A da Costa et al.	21
Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid	21
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	21
Editorial board	21
Variation in cervical cancer screening test utilization and results in a United States-based program	20
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists	20
3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer	20
Gamma secretase inhibitors, in combination with cytotoxic agents, decrease migration and invasion of uterine leiomyosarcoma	20
Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan	20
Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care	20
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy	20
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants	20
Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials	20
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings:	20
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer	20
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis	20
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global,	20
Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer	20
Assessing the readability of online health information regarding treatment modalities for gynecologic cancer patients	20
Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking	19
Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?	19
Molecular diversity in uterine carcinosarcoma: Beyond TP53	19
Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts	19
Patterns of recurrence and outcomes in vulvar extramammary Paget's disease	19
Feasibility of laparoscopic visceral-peritoneal debulking among patients with stage III–IV ovarian cancer: The ULTRA-LAP Pilot Trial	19
Financial toxicity among gynecologic oncology surgical patients	19
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review	19
Progression-free and overall survival of sequential platinum, taxane, and bevacizumab followed by immunotherapy may be equivalent to concurrent chemotherapy and immunotherapy among patients with recur	19
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells	19
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy	19
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Nor	19
Racial disparities in financial toxicity and social risks among urban endometrial cancer survivors	18
Hyperthermia-induced sensitization of platinum-resistant ovarian cancer cells: A potential strategy for overcoming drug resistance	18
Anti-αGal antibodies as an adjunct prognostic marker to CA-125/MUC16 in epithelial ovarian cancers	18
Beneath the layers: Association of preoperative sarcopenia with postoperative discharge destination and intensive care unit admission in patients with ovarian cancer	18
Complement C3 inhibition with pegcetacoplan controls malignant effusions in recurrent ovarian cancer: Interim results from a phase II trial	18
Venous thromboembolism prophylaxis in gynecologic cancer patients undergoing chemotherapy	18
A phase II study of avutometinib and defactinib in advanced or recurrent gynecologic mesonephric cancer: Interim results	18
Cesarean hysterectomy for placenta accreta spectrum: Temporal trends in the use of adjunct procedures	18
Clinician nudge to gynecologic oncology referral at suspected ovarian cancer diagnosis: A pilot study	18
Perioperative stress reduction in ovarian cancer (PRESERVE)	18
Addressing dynamic physical changes during neoadjuvant chemotherapy in ovarian cancer patients through prehabilitation implementation	18
Is uterine serous carcinoma an exclusively postmenopausal disease? Unveiling a distinct age-specific oncologic pattern	18
Trends in immune-related adverse events among patients with endometrial carcinoma	18
Comparative analysis of laparoscopic versus open inguinal lymphadenectomy in vulvar cancer surgery	18

Tranexamic acid use in advanced ovarian cancer patients undergoing cytoreductive surgery: A quality improvement study	18
Patient perspectives on palliative care in gynecologic oncology	18
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer	17
Thoracic epidural analgesia in Gynecologic Oncology ERAS: A waste of time or time to consider it as a standard of care? (2162)	17
Editorial board	17
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial	17
Foreword	17
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial	17
Health care services burden in ovarian cancer patients receiving PARP inhibitor maintenance treatment (377)	17
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative	17
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies	17
Geographic disparities in the United States gynecologic oncology workforce: Cancer care inequities and the paradox of more docs (014)	17
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)	17
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification	17
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA	17
Endometrial cancer recurrence after the use of an intrauterine manipulator during laparoscopic surgery: A retrospective cohort study (1216)	17
The impact of abortion restrictions on pregnant individuals with cancer in the United States: A statistical model (013)	17
Postoperative management and outcomes before and after closure of a women's health specialty unit at a tertiary care facility	17
Response to Letter to the Editor, Gilks et al.	17
Cervical Cancer Disparities in the American Indian/Alaska Native Population: Are Prevention Tools Being Utilized? (108)	17
Molecular targets and prognosis for uterine cancer: What is the role of mutations of unknown significance? (1262)	16
Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029)	16
TERT promoter mutations and gene amplification in endometrial cancer	16
Surgical universal euglycemic attainment during recovery (SUGAR) initiative: Sweet results through quality improvement (286)	16
The rising incidence of sex cord stromal ovarian tumors in the US: Who is most at risk? (442)	16
Social precarity as a novel framework for addressing psychosocial needs of patients with gynecologic cancers (2227)	16
Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)	16
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPE	16
Obesity-related cancers disproportionately affect women compared to men in the United States (399)	16
Frequency of actionable germline mutations identified through tumor next generation sequencing in a gynecologic cancer cohort (394)	16
Sentinel lymph node biopsy compared with systematic lymphadenectomy in patients with uterine carcinosarcoma (536)	16
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist	16
Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic (515)	16
Lived experience of women diagnosed with a gynecologic cancer in the height of the COVID-19 pandemic in New York City (508)	16
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	15
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study	15
Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group	15
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center	15
Utility of germline multi-gene panel testing in patients with endometrial cancer	15
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy	15
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia rece	15
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	15
Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308)	15
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma	15
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer	15
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival	15
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies	15
Early detection of endometrial cancer	15
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning	15
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carc	15
Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)	15
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes	15
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081	15
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer	15
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328	15
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwa	15
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)	15
Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?	15
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression	15
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/	15
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic	14
Factors influencing gynecologic risk reduction surgeries for BRCA1 or BRCA2 germline mutation carriers	14
Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population	14
Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer	14
Medical decision making from the perspective of the gynecologic oncology patient	14
Editorial Board	14
Impact of COVID-19 on missed diagnoses of uterine cancer: Who is most affected?	14
Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer	14
Gynecologic oncology patients with severe mental illness diagnosis are more likely to experience adverse outcomes during hospitalizations for cancer-directed treatment	14
Evaluation of the somatic and immunologic landscapes of primary and metastatic cervical cancer to better inform future clinical trial development	14
Implementation of automated social determinants of health screening in gynecologic oncology: A pilot study	14
Ovarian cancer patients demonstrating durable clinical benefit from neoadjuvant chemo-immunotherapy are associated with significant reductions in tumor-infiltrating CCR8+ regulatory T-cells	14
Characteristics of mismatch repair deficient endometrial cancer in a diverse cohort	14
The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer	14
p53 functional status is associated with survival among high-grade serous ovarian cancer patients with copy number signature one	14
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	13
Cervical adenocarcinoma: Factors and outcomes in early-stage patients	13
Identifying the molecular landscape of high risk uterine cancers: What mutations are most targetable? (1306)	13
Practice patterns and clinical outcomes in women with gynecologic malignancies who refuse blood products	13
STAT3 is a potential therapeutic target in cervical cancer (257)	13
The evaluation of study oversight in phase 3 gynecologic cancer trials on targeted therapies over the last ten years (2229)	13
Intraperitoneal therapy with engineered Newcastle disease virus encoding interleukin-12 in combination with PD-1 blockade for ovarian cancer	13
Research funding disparity in uterine cancer: An analysis of funding and race in relation to the burden of disease	13
Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis	13
P17 Evaluating a care delivery model for universal genetic testing among women with ovarian cancer	13
Harnessing EHR for goals of care: A randomized evaluation of electronic health record alerts for patients with gynecologic malignancies at risk for death in 6 months (165)	13
Gestational trophoblastic neoplasia (GTN): Does centralization of care impact clinical management? (2206)	13
Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagn	13
Novel serum target for early detection of ovarian cancer (2303)	13
Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study	13
How do we decide?: Provider opioid prescribing practices (2213)	13
Molecular landscape and clinical outcomes of ARID1A mutant ovarian and endometrial cancers (2276)	13
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population: Can technology standardize the message? (2171)	13
Genomic profiling and PD-L1 expression of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CIBI308ALTER-C201 trial (035)	13
Editorial Board	12